Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis

Although systemic etanercept was approved in 2004 for adults, the Food and Drug Administration (FDA) denied approval for use in children with psoriasis in 2008. Revision of the FDA's risk‐benefit assessment in response to understanding of disease burden, unmet medical need, and the effect of of...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2018-09, Vol.35 (5), p.688-689
Main Authors: Gatti, Jasmine, Lindstrom, Jill A., Beitz, Julie
Format: Article
Language:English
Subjects:
Children
Drug development
Etanercept
FDA approval
Medical equipment
Pediatrics
Psoriasis
systemic therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63
cites cdi_FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63
container_end_page 689
container_issue 5
container_start_page 688
container_title Pediatric dermatology
container_volume 35
creator Gatti, Jasmine
Lindstrom, Jill A.
Beitz, Julie
description Although systemic etanercept was approved in 2004 for adults, the Food and Drug Administration (FDA) denied approval for use in children with psoriasis in 2008. Revision of the FDA's risk‐benefit assessment in response to understanding of disease burden, unmet medical need, and the effect of off‐label use in children with psoriasis led to the 2016 approval as the first systemic biologic product for the treatment of children aged 4‐17 with moderate to severe psoriasis. This article delineates the thinking that led to this reconsideration. The underlying thinking paved the way to inform current pediatric drug development as the FDA continues to bring needed medical products to children.
doi_str_mv 10.1111/pde.13557
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2081552097</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2102888360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63</originalsourceid><addsrcrecordid>eNp10c9qFTEUBvAgir1WF76ABNzoYtpkziSZcVf6R4VCi-g6ZJIzkjIzGZNM5b5In7e5vVcXgtkEwi9fcvgIecvZCS_rdHF4wkEI9YxsuKhFxRvFnpMNUyCrljXyiLxK6Y4x1krJX5IjYExKUO2GPHxDG-bkHUaTfZhpGGhdHHVofSoHn-hVCI6a2dGLuP6kZ27ys0_5wM2yxHBvxt09zGbGaHHJdAiRpm3KOHlLc0STJ5zzDk3h6SmkOdCE9xiRLui8ybHIJYXoTfLpNXkxmDHhm8N-TH5cXX4__1Jd33z-en52XVkQoCrohOwVA7DQt25oLHKATjbG9sx2vRPA0AneKaM4OF6btul66IsG0xmUcEw-7HPLFL9WTFlPPlkcxzJJWJOuWcuFqFmnCn3_D70La5zL73TNWd22LUhW1Me9sjGkFHHQS_STiVvNmd6VpUtZ-qmsYt8dEtd-QvdX_mmngNM9-O1H3P4_Sd9eXO4jHwFXkZ-8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2102888360</pqid></control><display><type>article</type><title>Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Gatti, Jasmine ; Lindstrom, Jill A. ; Beitz, Julie</creator><creatorcontrib>Gatti, Jasmine ; Lindstrom, Jill A. ; Beitz, Julie</creatorcontrib><description>Although systemic etanercept was approved in 2004 for adults, the Food and Drug Administration (FDA) denied approval for use in children with psoriasis in 2008. Revision of the FDA's risk‐benefit assessment in response to understanding of disease burden, unmet medical need, and the effect of off‐label use in children with psoriasis led to the 2016 approval as the first systemic biologic product for the treatment of children aged 4‐17 with moderate to severe psoriasis. This article delineates the thinking that led to this reconsideration. The underlying thinking paved the way to inform current pediatric drug development as the FDA continues to bring needed medical products to children.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.13557</identifier><identifier>PMID: 30066378</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Children ; Drug development ; Etanercept ; FDA approval ; Medical equipment ; Pediatrics ; Psoriasis ; systemic therapy</subject><ispartof>Pediatric dermatology, 2018-09, Vol.35 (5), p.688-689</ispartof><rights>Published 2018. This article is a U.S. Government work and is in the public domain in the USA</rights><rights>Published 2018. This article is a U.S. Government work and is in the public domain in the USA.</rights><rights>Copyright © 2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63</citedby><cites>FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63</cites><orcidid>0000-0002-0712-0588</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30066378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gatti, Jasmine</creatorcontrib><creatorcontrib>Lindstrom, Jill A.</creatorcontrib><creatorcontrib>Beitz, Julie</creatorcontrib><title>Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>Although systemic etanercept was approved in 2004 for adults, the Food and Drug Administration (FDA) denied approval for use in children with psoriasis in 2008. Revision of the FDA's risk‐benefit assessment in response to understanding of disease burden, unmet medical need, and the effect of off‐label use in children with psoriasis led to the 2016 approval as the first systemic biologic product for the treatment of children aged 4‐17 with moderate to severe psoriasis. This article delineates the thinking that led to this reconsideration. The underlying thinking paved the way to inform current pediatric drug development as the FDA continues to bring needed medical products to children.</description><subject>Children</subject><subject>Drug development</subject><subject>Etanercept</subject><subject>FDA approval</subject><subject>Medical equipment</subject><subject>Pediatrics</subject><subject>Psoriasis</subject><subject>systemic therapy</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10c9qFTEUBvAgir1WF76ABNzoYtpkziSZcVf6R4VCi-g6ZJIzkjIzGZNM5b5In7e5vVcXgtkEwi9fcvgIecvZCS_rdHF4wkEI9YxsuKhFxRvFnpMNUyCrljXyiLxK6Y4x1krJX5IjYExKUO2GPHxDG-bkHUaTfZhpGGhdHHVofSoHn-hVCI6a2dGLuP6kZ27ys0_5wM2yxHBvxt09zGbGaHHJdAiRpm3KOHlLc0STJ5zzDk3h6SmkOdCE9xiRLui8ybHIJYXoTfLpNXkxmDHhm8N-TH5cXX4__1Jd33z-en52XVkQoCrohOwVA7DQt25oLHKATjbG9sx2vRPA0AneKaM4OF6btul66IsG0xmUcEw-7HPLFL9WTFlPPlkcxzJJWJOuWcuFqFmnCn3_D70La5zL73TNWd22LUhW1Me9sjGkFHHQS_STiVvNmd6VpUtZ-qmsYt8dEtd-QvdX_mmngNM9-O1H3P4_Sd9eXO4jHwFXkZ-8</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Gatti, Jasmine</creator><creator>Lindstrom, Jill A.</creator><creator>Beitz, Julie</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0712-0588</orcidid></search><sort><creationdate>201809</creationdate><title>Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis</title><author>Gatti, Jasmine ; Lindstrom, Jill A. ; Beitz, Julie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Children</topic><topic>Drug development</topic><topic>Etanercept</topic><topic>FDA approval</topic><topic>Medical equipment</topic><topic>Pediatrics</topic><topic>Psoriasis</topic><topic>systemic therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gatti, Jasmine</creatorcontrib><creatorcontrib>Lindstrom, Jill A.</creatorcontrib><creatorcontrib>Beitz, Julie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gatti, Jasmine</au><au>Lindstrom, Jill A.</au><au>Beitz, Julie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2018-09</date><risdate>2018</risdate><volume>35</volume><issue>5</issue><spage>688</spage><epage>689</epage><pages>688-689</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Although systemic etanercept was approved in 2004 for adults, the Food and Drug Administration (FDA) denied approval for use in children with psoriasis in 2008. Revision of the FDA's risk‐benefit assessment in response to understanding of disease burden, unmet medical need, and the effect of off‐label use in children with psoriasis led to the 2016 approval as the first systemic biologic product for the treatment of children aged 4‐17 with moderate to severe psoriasis. This article delineates the thinking that led to this reconsideration. The underlying thinking paved the way to inform current pediatric drug development as the FDA continues to bring needed medical products to children.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30066378</pmid><doi>10.1111/pde.13557</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-0712-0588</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0736-8046
ispartof Pediatric dermatology, 2018-09, Vol.35 (5), p.688-689
issn 0736-8046
1525-1470
language eng
recordid cdi_proquest_miscellaneous_2081552097
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects Children
Drug development
Etanercept
FDA approval
Medical equipment
Pediatrics
Psoriasis
systemic therapy
title Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reconsideration%20of%202008%20decision:%20Food%20and%20Drug%20Administration%20approval%20of%20etanercept%20for%20systemic%20treatment%20of%20moderate%20to%20severe%20pediatric%20psoriasis&rft.jtitle=Pediatric%20dermatology&rft.au=Gatti,%20Jasmine&rft.date=2018-09&rft.volume=35&rft.issue=5&rft.spage=688&rft.epage=689&rft.pages=688-689&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.13557&rft_dat=%3Cproquest_cross%3E2102888360%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3537-3956b7033c3b8df4ce133964acb0c9bd530ed5197a713d12a849b3bc3b3a9ae63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2102888360&rft_id=info:pmid/30066378&rfr_iscdi=true